Nu-Med Plus, Inc.: 5%+ holders

As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Nu-Med Plus, Inc. The largest reported stake is Fred Tejada's, at 9.7%. One filing is on record since August 25, 2026 (Schedule 13D, August 25, 2026).

Sell to companies like Nu-Med Plus, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-25 · Reporting person: Fred Tejada · Sole voting: 0 · Shared voting: 8,131,250 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-25
• Filed 2026-08-25 · Holder: Fred Tejada · Percent: 9.7% · SCHEDULE 13D
• Event date 2026-07-08 · Holder: Fred Tejada · Percent: 9.7% · Shares: 8,131,250 · SCHEDULE 13D

Nu-Med Plus, Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-25. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Nu-Med Plus, Inc. and the warning signs.

See Nu-Med Plus, Inc.'s free Snapshot Watch Nu-Med Plus, Inc.: email me the next time it files something

Free to see. No signup.

Want the whole picture on Nu-Med Plus, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Nu-Med Plus, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Nu-Med Plus, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Nu-Med Plus, Inc. by CUSIP 67021R104 and gives its principal executive office as 640 Belle Terre Building 2E, Port Jefferson, NY 11777 (SCHEDULE 13D, 2026-08-25).

Source of funds (Item 3)

Pursuant to a Voting Agreement dated July 9, 2026 and effective July 8, 2026 (the "Voting Agreement"), entered into among the Company, the Reporting Person and certain affiliated stockholders of the Company (The Hayde Family Revocable Trust dtd 9/21/2001 (trustee: William Hayde, the Company's CEO and a director), Keith Merrell (CFO and a director of the Company, together with his spouse as joint tenants), and Hanover International, Inc.Fred Tejada, SCHEDULE 13D, 2026-08-25

Purpose of Transaction (Item 4)

Fred Tejada

The Reporting Person acquired the Series A Preferred Stock in connection with the Closing of the Exchange, pursuant to which Avid Gold became a wholly-owned subsidiary of the Company. In connection with the Closing, the Reporting Person had been appointed as a member of the Company's Board of Directors effective July 7, 2026. The Voting Agreement was entered into pursuant to the terms of the Exchange Agreement, and the Series X Preferred Stock was issued in consideration for services agreed to be rendered. Following the Closing, the Voting Agreement requires the Voting Shareholders to vote their covered securities in favor of, among other matters, (i) fixing the number of directors constituting the Board of Directors at five, unless otherwise approved in writing pursuant to the Voting Agreement, (ii) electing and, if applicable, re-electing at least three directors designated in writing pursuant to the Voting Agreement and filling vacancies in such designated seats with persons so designated, (iii) increasing the Company's authorized Common Stock from 90,000,000 to 500,000,000 shares, (iv) effecting a 1-for-27 reverse stock split or a substantially similar reverse stock split ratio reasonably determined by the Board of Directors to be necessary or advisable, (v) redomiciling the Company from Utah to Nevada, (vi) changing the Company's name to such name as the Board of Directors may determine, (vii) approving the issuance of shares of Common Stock upon conversion of …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-25; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Also on the record for Nu-Med Plus, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Nu-Med Plus, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Nu-Med Plus, Inc. is mentioned again
• Find former Nu-Med Plus, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes